Wei Guo Selected Research

Tyrosine Kinase Inhibitors

8/2023	Development and clinical application of a liquid chromatography-tandem mass spectrometry-based assay to quantify eight tyrosine kinase inhibitors in human plasma.
12/2022	Current progress and open challenges for applying tyrosine kinase inhibitors in osteosarcoma.
5/2022	Long-term outcome and relapse patterns in Ewing sarcoma patients with extensive lung/pleural metastases after a complete response to systemic therapy.
1/2022	PI3K inhibitor impairs tumor progression and enhances sensitivity to anlotinib in anlotinib-resistant osteosarcoma.
9/2021	Phospho-EGFRTyr992 is synergistically repressed by co-inhibition of histone deacetylase (HDAC) and phosphatidylinositol 3-kinase (PI3K), which attenuates resistance to erlotinib in head and neck cancer cells.
7/2021	Apatinib plus ifosfamide and etoposide for relapsed or refractory osteosarcoma: A retrospective study in two centres.
1/2021	Anlotinib, Vincristine, and Irinotecan for Advanced Ewing Sarcoma After Failure of Standard Multimodal Therapy: A Two-Cohort, Phase Ib/II Trial.
1/2020	Anorexia, Hypertension, Pneumothorax, and Hypothyroidism: Potential Signs of Improved Clinical Outcome Following Apatinib in Advanced Osteosarcoma.
1/2020	Anlotinib suppresses tumor progression via blocking the VEGFR2/PI3K/AKT cascade in intrahepatic cholangiocarcinoma.
1/2019	Apatinib for Advanced Osteosarcoma after Failure of Standard Multimodal Therapy: An Open Label Phase II Clinical Trial.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Wei Guo Research Topics

Disease

662	Neoplasms (Cancer) 06/2024 - 11/2002
140	Neoplasm Metastasis (Metastasis) 06/2024 - 04/2003
81	Inflammation (Inflammations) 01/2024 - 07/2002
80	Infections 05/2024 - 12/2004
78	Hepatocellular Carcinoma (Hepatoma) 03/2024 - 09/2004
77	Osteosarcoma (Osteogenic Sarcoma) 01/2024 - 12/2002
69	Esophageal Squamous Cell Carcinoma 12/2023 - 12/2003
52	Lung Neoplasms (Lung Cancer) 10/2023 - 07/2005
50	Carcinogenesis 02/2024 - 12/2003
47	Esophageal Neoplasms (Esophageal Cancer) 02/2024 - 12/2003
47	Pain (Aches) 04/2023 - 07/2003
45	Breast Neoplasms (Breast Cancer) 04/2024 - 01/2006
45	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 12/2023 - 02/2002
38	Aortic Dissection 04/2024 - 07/2005
36	COVID-19 02/2024 - 01/2020
35	Squamous Cell Carcinoma of Head and Neck 07/2023 - 12/2002
35	Carcinoma (Carcinomatosis) 01/2022 - 11/2002
32	Colorectal Neoplasms (Colorectal Cancer) 06/2024 - 07/2005
32	Abdominal Aortic Aneurysm 12/2023 - 03/2002
31	Melanoma (Melanoma, Malignant) 02/2024 - 11/2010
31	Disease Progression 01/2024 - 10/2012
28	Wounds and Injuries (Trauma) 03/2024 - 03/2002
28	Adenocarcinoma 06/2023 - 02/2004
27	Sarcoma (Soft Tissue Sarcoma) 02/2024 - 10/2006
26	Hypoxia (Hypoxemia) 02/2023 - 03/2006
24	Prostatic Neoplasms (Prostate Cancer) 01/2023 - 11/2011
23	Body Weight (Weight, Body) 04/2024 - 07/2008
22	Heart Failure 01/2024 - 04/2008
21	Hemorrhage 03/2024 - 10/2007
21	Adenocarcinoma of Lung 12/2023 - 01/2013
20	Hyperalgesia 01/2019 - 07/2002
18	Myocardial Infarction 04/2024 - 01/2006
18	Obesity 01/2024 - 01/2006
18	Colonic Neoplasms (Colon Cancer) 01/2024 - 03/2005
17	Endoleak 04/2024 - 03/2002
17	Lymphatic Metastasis 05/2023 - 02/2005
17	Necrosis 12/2022 - 02/2002
16	Fibrosis (Cirrhosis) 03/2024 - 02/2002
16	Stroke (Strokes) 01/2024 - 11/2012
16	Cardiovascular Diseases (Cardiovascular Disease) 01/2024 - 06/2006
16	Squamous Cell Carcinoma (Epidermoid Carcinoma) 04/2023 - 11/2002
15	Lymphoma (Lymphomas) 01/2024 - 02/2005
15	Hypertrophy 10/2023 - 05/2007
15	Ewing Sarcoma (Sarcoma, Ewing) 01/2023 - 06/2006
14	Hypertension (High Blood Pressure) 04/2024 - 10/2003
14	Thrombosis (Thrombus) 04/2024 - 03/2002
14	Type 2 Diabetes Mellitus (MODY) 11/2023 - 01/2006
13	Pathologic Constriction (Stenosis) 04/2024 - 04/2012
13	Reperfusion Injury 04/2024 - 01/2006

Drug/Important Bio-Agent (IBA)

188	Proteins (Proteins, Gene)FDA Link 02/2024 - 02/2003
107	Biomarkers (Surrogate Marker)IBA 01/2024 - 03/2007
57	Messenger RNA (mRNA)IBA 05/2024 - 10/2002
57	MicroRNAs (MicroRNA)IBA 12/2023 - 01/2011
56	Long Noncoding RNAIBA 04/2024 - 04/2015
48	CytokinesIBA 04/2024 - 03/2005
39	Small Interfering RNA (siRNA)IBA 04/2024 - 03/2005
37	Therapeutic UsesIBA 11/2023 - 07/2012
37	DNA (Deoxyribonucleic Acid)IBA 09/2023 - 12/2003
35	RNA (Ribonucleic Acid)IBA 01/2024 - 04/2015
27	Cisplatin (Platino)FDA LinkGeneric 01/2023 - 02/2002
26	EnzymesIBA 02/2024 - 10/2003
24	CateninsIBA 06/2024 - 01/2011
24	Glucose (Dextrose)FDA LinkGeneric 05/2024 - 04/2008
22	Phosphotransferases (Kinase)IBA 11/2023 - 10/2004
21	LipidsIBA 04/2024 - 09/2013
19	AntigensIBA 05/2023 - 01/2006
17	Interleukin-6 (Interleukin 6)IBA 01/2024 - 05/2009
17	LigandsIBA 10/2023 - 06/2005
17	Antineoplastic Agents (Antineoplastics)IBA 01/2022 - 11/2002
16	Doxorubicin (Adriamycin)FDA LinkGeneric 03/2024 - 12/2003
16	Reactive Oxygen Species (Oxygen Radicals)IBA 09/2022 - 01/2016
16	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2022 - 03/2006
15	Peptides (Polypeptides)IBA 01/2024 - 04/2004
15	Fluorouracil (Carac)FDA LinkGeneric 06/2023 - 11/2002
15	Transcription Factors (Transcription Factor)IBA 05/2023 - 11/2008
15	Hormones (Hormone)IBA 01/2022 - 05/2012
14	Immune Checkpoint InhibitorsIBA 04/2024 - 01/2018
14	ChemokinesIBA 04/2024 - 03/2003
14	C-Reactive ProteinIBA 01/2024 - 06/2013
14	VaccinesIBA 11/2023 - 09/2008
14	CollagenIBA 06/2023 - 02/2002
14	Anti-Bacterial Agents (Antibiotics)IBA 01/2023 - 04/2011
13	Indicators and Reagents (Reagents)IBA 01/2024 - 02/2006
13	Tumor Biomarkers (Tumor Markers)IBA 11/2023 - 08/2012

Therapy/Procedure

247	Therapeutics 04/2024 - 02/2004
105	Drug Therapy (Chemotherapy) 03/2024 - 04/2003
61	Radiotherapy 02/2024 - 04/2003
60	Immunotherapy 03/2024 - 03/2003
56	Stents 04/2024 - 03/2002
48	Endovascular Aneurysm Repair 04/2024 - 08/2009
32	Prostheses and Implants (Prosthesis) 01/2024 - 12/2004
31	Esophagectomy 02/2024 - 05/2012
25	Neoadjuvant Therapy 12/2023 - 07/2004
23	Percutaneous Coronary Intervention 08/2023 - 11/2013
17	Limb Salvage 07/2022 - 10/2006
16	Operative Surgical Procedures 11/2023 - 04/2003
16	Aftercare (After-Treatment) 01/2023 - 03/2006
16	Curettage 05/2022 - 12/2004
14	Lasers (Laser) 01/2024 - 08/2014
13	Length of Stay 11/2023 - 08/2009